Parexel and Datavant, which focuses on healthcare technology, are partnering to improve the design and operations of clinical studies and the generation of real-world evidence.
The partnership is designed to connect healthcare data from a number of real-world and clinical data sources to spur improved drug development and commercialization, the companies said.
Datavant targets secure de-identification and linking of healthcare datasets.
“The exponential growth of healthcare data offers both an opportunity to incorporate this wealth of data into the clinical study processes and commercial evidence generation, and a challenge, given the disparate sources where a patient’s healthcare data may be contained,” Jason Martin, Parexel’s VP of Global Data Operations, said in a statement.
San Francisco-based Datavant’s tech allows the linking of traditional healthcare data sources like electronic medical records, claims and diagnostics with other emerging sources such as genomics, socioeconomic data, information from wearable devices and behavioral data.
Travis May, Datavant’s chief executive, said the partnership will provide “an opportunity to answer some of the most difficult questions in drug development and commercialization for the ultimate benefit of patients.”